🚨Exciting results from the #RECOVERY trial #preprint of #Tocalizumab (Toci) in hospitalized people w/ #COVID19
-reduced 28-day mortality (29 vs 33%; NNT)
-decreased likelihood of requiring MV (33% vs 38%)
-shorter hospital stay (median 20 vs >28 days)
https://medrxiv.org/content/10.1101/2021.02.11.21249258v1.full.pdf
1/
Exciting results from the #RECOVERY trial #preprint of #Tocalizumab (Toci) in hospitalized people w/ #COVID19-reduced 28-day mortality (29 vs 33%; NNT)-decreased likelihood of requiring MV (33% vs 38%)-shorter hospital stay (median 20 vs >28 days) https://medrxiv.org/content/10.1101/2021.02.11.21249258v1.full.pdf1/
Exciting results from the #RECOVERY trial #preprint of #Tocalizumab (Toci) in hospitalized people w/ #COVID19-reduced 28-day mortality (29 vs 33%; NNT)-decreased likelihood of requiring MV (33% vs 38%)-shorter hospital stay (median 20 vs >28 days) https://medrxiv.org/content/10.1101/2021.02.11.21249258v1.full.pdf1/
Exciting results from the #RECOVERY trial #preprint of #Tocalizumab (Toci) in hospitalized people w/ #COVID19-reduced 28-day mortality (29 vs 33%; NNT)-decreased likelihood of requiring MV (33% vs 38%)-shorter hospital stay (median 20 vs >28 days) https://medrxiv.org/content/10.1101/2021.02.11.21249258v1.full.pdf1/
They randomized 4116 pts to weight-based Toci vs usual care (UC):
-groups were balanced: mostly male (>65%), older (>60 yo), & w/ comorbidities (>55%)
-most patients (82%) also received dexamethasone
-they received Toci early in hospitalization but were 7-14 days after onset
2/
They randomized 4116 pts to weight-based Toci vs usual care (UC):-groups were balanced: mostly male (>65%), older (>60 yo), & w/ comorbidities (>55%)-most patients (82%) also received dexamethasone-they received Toci early in hospitalization but were 7-14 days after onset2/
They randomized 4116 pts to weight-based Toci vs usual care (UC):-groups were balanced: mostly male (>65%), older (>60 yo), & w/ comorbidities (>55%)-most patients (82%) also received dexamethasone-they received Toci early in hospitalization but were 7-14 days after onset2/
They randomized 4116 pts to weight-based Toci vs usual care (UC):-groups were balanced: mostly male (>65%), older (>60 yo), & w/ comorbidities (>55%)-most patients (82%) also received dexamethasone-they received Toci early in hospitalization but were 7-14 days after onset2/
Notably, only 83% of patients in the Toci group actually received Toci (plus 2.6% randomized to the UC group got Toci); this would decrease the effect size and bias the towards null.

This means their ITT analysis is probably *underestimating* the true effect size somewhat.

3/
To their credit, despite the fact that intention-to-treat (ITT) underestimates the effect they don't waste even 1 second of my time with an "as treated analysis."
Even in the supplement. This is a mark of legit science.

Statistically speaking this is a "nothing but net" shot
4/
In terms of outcomes, pts randomized to Toci had clinically meaningful Δ:
-decreased 28 day mortality (29 vs 33%; NNT 25)
-lower likelihood of requiring IMV (12 vs 15%; NNT 33)
-lower likelihood of requiring RRT (5 vs 7%; NNT 50)
-shorter hospital LOS (median 20 vs 28 days)
5/
In terms of outcomes, pts randomized to Toci had clinically meaningful Δ:-decreased 28 day mortality (29 vs 33%; NNT 25)-lower likelihood of requiring IMV (12 vs 15%; NNT 33)-lower likelihood of requiring RRT (5 vs 7%; NNT 50)-shorter hospital LOS (median 20 vs 28 days)5/
In terms of outcomes, pts randomized to Toci had clinically meaningful Δ:-decreased 28 day mortality (29 vs 33%; NNT 25)-lower likelihood of requiring IMV (12 vs 15%; NNT 33)-lower likelihood of requiring RRT (5 vs 7%; NNT 50)-shorter hospital LOS (median 20 vs 28 days)5/
One concern is that Toci can cause arrythmias & increase the risk of secondary infections.

Notably there was no increase in cardiac arrythmias, unexplained mortality, or infection related mortality.

This suggests that a single dose of Toci does not have major side effects.
6/
One concern is that Toci can cause arrythmias & increase the risk of secondary infections. Notably there was no increase in cardiac arrythmias, unexplained mortality, or infection related mortality.This suggests that a single dose of Toci does not have major side effects.6/
One concern is that Toci can cause arrythmias & increase the risk of secondary infections. Notably there was no increase in cardiac arrythmias, unexplained mortality, or infection related mortality.This suggests that a single dose of Toci does not have major side effects.6/
"BuT wHaT aBoUt AlL tHe NeGaTiVe TrIaLs?"

There's definitely been a back and forth in the Tocilizumab/COVID19 literature. This is a situation where we really need to look closely at the individual studies...

(Shamelessly stole this GIF from my friend @NickJohnsonMD btw)
7/
I will do a blog post on this, but here's the quick version: These studies vary alot!

-Intervention: some gave 1 dose Toci, some ≥2
-Population: some include only ICU/MV patients, some exclude all ICU or MV patients, some gave Dex, some didn't
-Most are underpowered (n<300)
8/
The authors do include a Forest plot, but their methodology seems a bit sketchy...

Specifically, they double up the control groups in a couple studies & appear to use a fixed effects model, despite reasonably high heterogeneity.

To illustrate, compare their analysis to mine:
9/
The authors do include a Forest plot, but their methodology seems a bit sketchy...Specifically, they double up the control groups in a couple studies & appear to use a fixed effects model, despite reasonably high heterogeneity.To illustrate, compare their analysis to mine:9/
The authors do include a Forest plot, but their methodology seems a bit sketchy...Specifically, they double up the control groups in a couple studies & appear to use a fixed effects model, despite reasonably high heterogeneity.To illustrate, compare their analysis to mine:9/
The authors do include a Forest plot, but their methodology seems a bit sketchy...Specifically, they double up the control groups in a couple studies & appear to use a fixed effects model, despite reasonably high heterogeneity.To illustrate, compare their analysis to mine:9/
Overall this is a rigorously done study & analysis. I'm curious to see how this section changes in peer review.

I'm also curious to see if they do a cost-effectiveness analysis. My hypothesis would be the big reductions in IMV, RRT, and LOS would more than pay for the Toci.
10/
🥡Takehome point: RECOVERY is a large well-done RCT that convincingly shows that #tocilizumab is beneficial given in combination w/ #dexamethasone in severe/critical #COVID19 infxn

Two large RCTs (REMAP-CAP & RECOVERY) replicate this finding. This should change our practice
11/
To put this another way; I've gotten on and off the Toci train đźš‚ over the last year, but these latest studies are compelling and make me a believer.

If I got very sick with COVID19, I would want to receive #Tocilizumab (along with #dexamethasone of course).
12/
Disclosures: Sadly I receive no đź’° from the makers of Tocilzumab...
13/13
You can follow @nickmmark.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.